These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide (RS-82856). Venuti MC; Jones GH; Alvarez R; Bruno JJ J Med Chem; 1987 Feb; 30(2):303-18. PubMed ID: 3027339 [TBL] [Abstract][Full Text] [Related]
9. Inhibitors of cyclic AMP phosphodiesterase. 1. Analogues of cilostamide and anagrelide. Jones GH; Venuti MC; Alvarez R; Bruno JJ; Berks AH; Prince A J Med Chem; 1987 Feb; 30(2):295-303. PubMed ID: 3027338 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo. Minami N; Suzuki Y; Yamamoto M; Kihira H; Imai E; Wada H; Kimura Y; Ikeda Y; Shiku H; Nishikawa M Life Sci; 1997; 61(25):PL 383-9. PubMed ID: 9416770 [TBL] [Abstract][Full Text] [Related]
17. [Research and development of cilostazol: an antiplatelet agent]. Nishi T; Kimura Y; Nakagawa K Yakugaku Zasshi; 2000 Dec; 120(12):1247-60. PubMed ID: 11193377 [TBL] [Abstract][Full Text] [Related]
18. Effect of cAMP phosphodiesterase inhibitors on ADP-induced shape change, cAMP and nucleoside diphosphokinase activity of rabbit platelets. Lam SC; Guccione MA; Packham MA; Mustard JF Thromb Haemost; 1982 Apr; 47(2):90-5. PubMed ID: 6285543 [TBL] [Abstract][Full Text] [Related]
19. A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties. Alvarez R; Banerjee GL; Bruno JJ; Jones GL; Littschwager K; Strosberg AM; Venuti MC Mol Pharmacol; 1986 Jun; 29(6):554-60. PubMed ID: 3012320 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and in vitro antiplatelet activity of new 4-(1-piperazinyl)coumarin derivatives. Human platelet phosphodiesterase 3 inhibitory properties of the two most effective compounds described and molecular modeling study on their interactions with phosphodiesterase 3A catalytic site. Roma G; Di Braccio M; Grossi G; Piras D; Leoncini G; Bruzzese D; Signorello MG; Fossa P; Mosti L J Med Chem; 2007 Jun; 50(12):2886-95. PubMed ID: 17500510 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]